Bacterial and Viral Specimen Collection Market Report 2025

The bacterial and viral specimen collection market size has grown rapidly in recent years. It will grow from $20.95 billion in 2024 to $23.86 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to increasing demand for accurate and early diagnosis, the rise in viral outbreak incidences, greater government funding, growing global healthcare expenditure, and the expansion of telemedicine.

The bacterial and viral specimen collection market size is expected to see rapid growth in the next few years. It will grow to $39.68 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to the expansion of global disease surveillance networks, increasing investment in pandemic preparedness, the rising prevalence of infectious diseases, growing antimicrobial resistance, and the increasing incidence of bacterial infections. Key trends expected during this period include technological advancements, the integration of digital tracking systems, wider adoption of non-invasive specimen collection methods, the use of microfluidic devices, and the implementation of automated specimen tracking solutions.

The rising prevalence of infectious diseases is expected to drive the growth of the bacterial and viral specimen collection market in the coming years. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread between individuals through direct or indirect contact. Increasing urbanization plays a key role in this rise, as higher population density and closer human interaction accelerate disease transmission, creating favorable conditions for pathogens to spread rapidly across communities. Bacterial and viral specimen collection is essential for managing infectious diseases, as it provides reliable samples for accurate detection and diagnosis, enabling timely medical intervention and effective treatment strategies. For instance, in March 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that tuberculosis cases in the United States increased from 8,320 in 2022 to 9,615 in 2023, a rise of 1,295 cases, with the incidence rate climbing from 2.5 to 2.9 per 100,000 persons. This highlights a significant upward trend, underscoring the growing demand for efficient specimen collection methods.

Companies in the bacterial and viral specimen collection market are increasingly focusing on innovations such as viral DNA and RNA extraction kits to improve pathogen detection and analysis. These kits enable the isolation and purification of viral genetic material from clinical samples, ensuring faster, more accurate molecular testing and diagnosis. For example, in April 2024, New England Biolabs, a US-based life sciences company, launched the Monarch Mag Viral DNA and RNA Extraction Kit. This magnetic bead-based purification system is designed for high-sensitivity extraction of viral DNA and RNA from sample types such as respiratory swabs, saliva, and enriched wastewater. The kit is compatible with both manual and automated workflows, including KingFisher Flex and Agilent Bravo platforms, enabling scalable, high-throughput processing. By enhancing detection sensitivity for low viral loads, incorporating carrier RNA for improved recovery, and supporting downstream applications such as qPCR, RT-qPCR, ddPCR, and next-generation sequencing (NGS), the kit addresses critical needs in infectious disease diagnostics, viral genome sequencing, and environmental surveillance.

In April 2024, Eurofins Scientific SE, a Luxembourg-based testing laboratory company, acquired Ascend Clinical LLC, a US-based clinical laboratory specializing in infectious disease and renal testing. This acquisition aims to strengthen Eurofins’ position in the US market by expanding its clinical client base and enhancing its renal and transplant testing services. By integrating Ascend’s expertise with Eurofins’ extensive laboratory network, advanced technology, and broad geographic reach, the company seeks to elevate patient care and reinforce its capabilities in bacterial and viral specimen collection and testing.

Major players in the bacterial and viral specimen collection market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Becton Dickinson and Company, Lonza Group AG, Hologic Inc., bioMérieux SA, Quidel Corporation, QIAGEN N.V., DiaSorin S.p.A., Greiner Bio-One International GmbH, Spectrum Solutions LLC, Hardy Diagnostics Inc., EKF Diagnostics Holdings Plc, Trinity Biotech Plc, Puritan Medical Products Company LLC, Wuxi NEST Biotechnology Co. Ltd., Copan Diagnostics Inc., VIRCELL S.L., Medical Wire & Equipment Co. Ltd., HiMedia Laboratories Pvt. Ltd., Longhorn Vaccines and Diagnostics LLC, and Beaver Biomedical Engineering Co. Ltd.

North America was the largest region in the bacterial and viral specimen collection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bacterial and viral specimen collection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bacterial and viral specimen collection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Bacterial and viral specimen collection refers to the systematic process of obtaining biological samples - such as nasal or throat swabs, body fluids, or tissue samples - to detect, identify, and analyze bacterial or viral pathogens that cause infections. This process requires sterile equipment, proper collection techniques, and appropriate storage or transport methods to preserve the integrity and viability of microorganisms for accurate laboratory testing.

The primary product categories of bacterial and viral specimen collection are bacterial specimen collection and viral specimen collection. Bacterial specimen collection involves obtaining biological samples from patients using aseptic methods to detect, isolate, and identify disease-causing bacteria. These collections are applied in various areas such as diagnostics and research and are used by end users including hospitals and clinics, diagnostic laboratories, academic and research institutions, and others.

The bacterial and viral specimen collection market research report is one of a series of new reports that provides bacterial and viral specimen collection market statistics, including bacterial and viral specimen collection industry global market size, regional shares, competitors with a bacterial and viral specimen collection market share, detailed bacterial and viral specimen collection market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial and viral specimen collection industry. This bacterial and viral specimen collection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bacterial and viral specimen collection market consists of revenues earned by entities by providing services, such as microbiological sampling, blood sample collection, specimen transport, documentation and data management, and quality assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.